Article (Scientific journals)
Focus sur le tirzépatide, un double agoniste unimoléculaire GIP-GLP-1 dans le diabète de type 2.
Scheen, André; Radermecker, Régis; Paquot, Nicolas
2022In Revue Médicale Suisse, 18 (792), p. 1539-1544
Peer Reviewed verified by ORBi
 

Files


Full Text
prise position sfd 2021.pdf
Publisher postprint (218.38 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Blood Glucose; Glucagon-Like Peptide-1 Receptor; Hypoglycemic Agents; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; OYN3CCI6QE (tirzepatide); Diabetes Mellitus, Type 2/drug therapy/metabolism; Glucagon-Like Peptide-1 Receptor/agonists; Humans; Hypoglycemic Agents/therapeutic use
Abstract :
[en] Tirzepatide is a unimolecular dual agonist of both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, which is developed as once-weekly injection for the treatment of type 2 diabetes. Because of the complementarity of action of the two incretins, tirzepatide showed, in a dose-dependent manner (5, 10 and 15 mg), a better efficacy (greater reduction in HbA1c and body weight) compared with placebo, basal insulin and two GLP-1 analogues (dulaglutide and semaglutide) in the SURPASS program. Its cardiovascular protection (versus dulaglutide) is currently tested in SURPASS-CVOT. Finally, studies for the treatment of obesity and metabolic associated fatty liver disease are also ongoing. Gastrointestinal tolerance of tirzepatide appears comparable to that of GLP-1 analogues, except more diarrhoea.
Disciplines :
Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology
Author, co-author :
Scheen, André  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques ; Service de diabétologie, nutrition et maladies métaboliques, Centre hospitalier  ; Unité de pharmacologie clinique, Centre interdisciplinaire de recherche sur le
Radermecker, Régis ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques ; Service de diabétologie, nutrition et maladies métaboliques, Centre hospitalier  ; Unité de pharmacologie clinique, Centre interdisciplinaire de recherche sur le
Paquot, Nicolas ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques ; Service de diabétologie, nutrition et maladies métaboliques, Centre hospitalier
Language :
French
Title :
Focus sur le tirzépatide, un double agoniste unimoléculaire GIP-GLP-1 dans le diabète de type 2.
Alternative titles :
[en] Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes.
Publication date :
24 August 2022
Journal title :
Revue Médicale Suisse
ISSN :
1660-9379
Publisher :
Medecine et Hygiène, Ch
Volume :
18
Issue :
792
Pages :
1539-1544
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 24 February 2023

Statistics


Number of views
90 (3 by ULiège)
Number of downloads
1 (1 by ULiège)

Scopus citations®
 
7
Scopus citations®
without self-citations
1
OpenCitations
 
0

Bibliography


Similar publications



Contact ORBi